Scarica l'app Stockscreener
5.30
6.43%
0.32
Dopo l'orario di chiusura:
5.30
Precedente Chiudi:
$4.98
Aprire:
$4.99
Volume 24 ore:
1.44M
Relative Volume:
3.12
Capitalizzazione di mercato:
$414.07M
Reddito:
$351.37M
Utile/perdita netta:
$-174.01M
Rapporto P/E:
-2.5604
EPS:
-2.07
Flusso di cassa netto:
$-126.94M
1 W Prestazione:
+13.25%
1M Prestazione:
+31.84%
6M Prestazione:
+57.27%
1 anno Prestazione:
+76.08%
Intervallo 1D:
$4.98
$5.335
Intervallo di 1 settimana:
$4.56
$5.335
Portata 52W:
$2.455
$5.335
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
857-204-8109
Indirizzo
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
5.30 | 389.07M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss - TradingView
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline - Stock Titan
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings - Benzinga
Risk Off: Can Atea Pharmaceuticals Inc navigate macro headwinds2025 Key Highlights & AI Driven Price Predictions - baoquankhu1.vn
AVIR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 - The Manila Times
Details on Atea Pharma's Q4 and 2025 finances coming March 5 - Stock Titan
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - MarketBeat
AVIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atea Pharmaceuticals presents preclinical results of AT-587 - marketscreener.com
No approved hepatitis E drugs: experimental pill shows powerful lab results - Stock Titan
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 - Bitget
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR - Defense World
Is Atea Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Low Risk Entry Point Tips - mfd.ru
Published on: 2026-02-08 21:54:48 - baoquankhu1.vn
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2%Here's What Happened - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2%Time to Sell? - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 2% – Here’s What Happened - Defense World
Street Watch: Is Atea Pharmaceuticals Inc attractive for institutional investorsIndex Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
Aug Closing: Is Atea Pharmaceuticals Inc still a buy after recent gains2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Sectors: Will BIIB benefit from sector rotationJuly 2025 Final Week & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will Atea Pharmaceuticals Inc. face regulatory challengesDividend Hike & Weekly Breakout Opportunity Watchlist - mfd.ru
Risk Hedge: Can Atea Pharmaceuticals Inc stock double in the next yearJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Update Report: Is Atea Pharmaceuticals Inc stock undervalued right now2025 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug EndMonth: Can The AZEK Company Inc stock double in the next yearJuly 2025 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain - 富途牛牛
Can Atea Pharmaceuticals Inc expand into new marketsEarnings Recap Report & Risk Managed Trade Strategies - baoquankhu1.vn
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks - Yahoo Finance
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference - MarketBeat
Is Atea Pharmaceuticals Inc. still a buy after recent gainsBlue Chip Stock Analysis & Daily Tips From Top Market Analysts - bollywoodhelpline.com
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Pharmaceutical Technology
Dip Buying: Can Atea Pharmaceuticals Inc stock double in the next year2025 Bull vs Bear & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR) and Penumbra (PEN) - The Globe and Mail
Buyout Rumor: Is Atea Pharmaceuticals Inc a momentum stockTrend Reversal & Expert Curated Trade Setups - baoquankhu1.vn
Wall Street Recap: Will Atea Pharmaceuticals Inc face regulatory challengesTrade Volume Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Options Flow: Will Atea Pharmaceuticals Inc stock maintain dividend yieldJuly 2025 Patterns & Smart Money Movement Tracker - Bộ Nội Vụ
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock - Yahoo Finance
How Atea Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда
What is the fair value of Atea Pharmaceuticals Inc. stock nowEarnings Miss & Community Consensus Stock Picks - ulpravda.ru
Risk Off: Will Atea Pharmaceuticals Inc stock attract more institutional investorsTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Atea Pharmaceuticals to highlight strategic priorities for FY26 - Yahoo Finance
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Will Atea Pharmaceuticals Inc. stock attract more institutional investorsTrade Ideas & Safe Capital Growth Stock Tips - ulpravda.ru
Why Atea Pharmaceuticals Inc. stock is popular among millennials2025 Trading Volume Trends & Community Consensus Trade Alerts - Улправда
Will Atea Pharmaceuticals Inc. stock deliver strong dividend growthGlobal Markets & Precise Buy Zone Identification - ulpravda.ru
Atea Pharmaceuticals Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Atea Pharmaceuticals Advances Phase 3 Trials for HCV Treatment Regimen, Anticipates Significant Milestones in 2026 - Quiver Quantitative
New hepatitis C and E treatments move toward key human clinical trials in 2026 - Stock Titan
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atea Pharmaceuticals Inc Azioni (AVIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Murphy Polly A. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
86,045 |
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):